Conexeu Sciences Opens Vancouver R&D Hub

Conexeu Sciences Inc. (NASDAQ: CNXU) opened a new research and development facility inside adMare BioInnovations’ M4 Innovation Centre in Vancouver, Canada, marking a key step in scaling its regenerative tissue platform. The company held a ribbon-cutting ceremony on June 23, 2026, to mark the milestone and celebrate its next phase of growth. Conexeu becomes one of the first tenants inside the 30,000-square-foot M4 Innovation Centre, a purpose-built hub designed to support emerging life sciences companies.

Expanding a Proprietary Tissue Regeneration Platform

The new lab will anchor Conexeu’s ongoing research, product development and commercialization work, centered on its proprietary CXU™ extracellular matrix platform. Scientists at the facility will advance B.R.E.A.S.T.™, a 3D-bioprinted breast matrix that helps the body regrow natural tissue after mastectomy. Co-Founder and Chief Scientific Officer Dr. Claudia Chavez-Munoz says the facility strengthens the company’s research capabilities as it pursues applications across tissue regeneration, wound care and breast reconstruction.

Targeting Large, Underserved Markets

CXU™ restores soft tissue lost to injury, aging and GLP-1-associated tissue loss, using a thermosensitive gel that transitions from fluid to stable form at body temperature within about ten minutes. Preclinical studies show the platform supports enhanced healing, organized scaffold formation and a low inflammatory profile that promotes cell migration and new tissue growth. Conexeu holds full patent rights across the U.S., E.U., Japan and Australia (with a pending Canadian patent), giving it complete control over licensing and expansion without royalty obligations.

Building Toward Regulatory Milestones

Conexeu targets multi-billion-dollar markets spanning wound care, periodontal applications, and facial and body contouring, including GLP-1-driven skin laxity. The company is pursuing a predicate-based U.S. regulatory pathway and plans to submit a 510(k) application in early 2027 for its initial indication. Recent moves, including board expansion and new leadership hires with aesthetics-industry experience, signal the company’s push toward commercial readiness following its May 2026 Nasdaq debut.

Strategic Investment Summary

• Facility Launch: Conexeu Sciences Inc. (NASDAQ: CNXU) opened a new R&D lab at adMare BioInnovations’ M4 Innovation Centre in Vancouver, Canada.
• Core Technology: The CXU™ platform uses a patented, thermosensitive extracellular matrix to restore soft tissue lost to injury, aging or GLP-1 treatments.
• Lead Program: B.R.E.A.S.T.™, a 3D-bioprinted breast matrix, targets natural tissue regeneration following mastectomy.
• IP Position: Conexeu holds full, royalty-free rights to its platform across the U.S., E.U., Japan and Australia, with a Canadian patent pending.
• Market Opportunity: The company targets multi-billion-dollar segments including wound care, periodontal treatment, and facial and body contouring.
• Regulatory Path: Conexeu plans a 510(k) submission in early 2027 for its first indication, following a predicate-based U.S. strategy.
• Recent Momentum: The company expanded its board and leadership team shortly after its May 2026 Nasdaq listing, signaling a push toward commercialization.

Find out more about the latest technology milestones and regulatory filings at the Conexeu Sciences investor portal.